L-selectin is a possible biomarker for individual PML risk in natalizumab-treated MS patients (Q47832232)
Jump to navigation
Jump to search
scientific article published on 7 August 2013
Language | Label | Description | Also known as |
---|---|---|---|
English | L-selectin is a possible biomarker for individual PML risk in natalizumab-treated MS patients |
scientific article published on 7 August 2013 |
Statements
1 reference
L-selectin is a possible biomarker for individual PML risk in natalizumab-treated MS patients (English)
1 reference
1 reference
Tania Kümpfel
1 reference
Bernd C Kieseier
1 reference
Heinz Wiendl
1 reference
Dorothea Buck
1 reference
Ralf Gold
1 reference
Brigitte Wildemann
1 reference
Sven G Meuth
1 reference
Christoph Kleinschnitz
1 reference
Kerstin Göbel
1 reference
Tilman Schneider-Hohendorf
1 reference
Vilmos Posevitz
1 reference
Johanna Breuer
1 reference
Susanne Windhagen
1 reference
Bruno Brochet
1 reference
Patrick Vermersch
1 reference
Christine Lebrun-Frenay
1 reference
Anita Posevitz-Fejfár
1 reference
Ruggero Capra
1 reference
Luisa Imberti
1 reference
Vera Straeten
1 reference
Juergen Haas
1 reference
Joachim Havla
1 reference
Ingrid Meinl
1 reference
Kyle Niessen
1 reference
Susan Goelz
1 reference
Clemens Warnke
1 reference
John Foley
1 reference
Andrew Chan
1 reference
David Brassat
1 reference
7 August 2013
1 reference
1 reference
81
1 reference
10
1 reference
865-871
1 reference